West Paces Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

West Paces Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6	Closed	-$1.1K	–	649
2021 Q2	$1.1K	Buy	+6	New	+$1.03K	﹤0.01%	595
2019 Q4	–	Sell	-2	Closed	-$196	–	504
2019 Q3	$196	Buy	+2	New	+$225	﹤0.01%	483
2019 Q1	–	Sell	-10	Closed	-$974	–	489
2018 Q4	$974	Hold	10	–	–	﹤0.01%	468
2018 Q3	$1.39K	Hold	10	–	–	﹤0.01%	458
2018 Q2	$1.24K	Buy	+10	New	+$1.17K	﹤0.01%	466
2017 Q3	–	Sell	-23	Closed	-$2.8K	–	516
2017 Q2	$2.8K	Hold	23	–	–	﹤0.01%	430
2017 Q1	$2.79K	Sell	23 -34	-60%	-$4.38K	﹤0.01%	429
2016 Q4	$6.97K	Buy	+57	New	+$6.97K	0.01%	381

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

West Paces Advisors's ALXN Position: Q3 2021 in Review

West Paces Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6 shares — an estimated $1.1K sold.

West Paces Advisors first reported a position in ALXN in Q4 2016 and held it in 8 quarters. The position peaked at $6.97K in Q4 2016. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

West Paces Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
West Paces Advisors sold 6 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.1K.
West Paces Advisors first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 8 quarters.
West Paces Advisors's Alexion Pharmaceuticals position peaked at $6.97K in Q4 2016.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on West Paces Advisors's 13F filing for Q3 2021, filed 20 Dec 2023.